Key Highlights

  • Neumora Therapeutics, Inc. (NASDAQ:NMRA) rose about 7.9% near USD 0.41 on Monday, October 26, 2026, months after navacaprant failed in two Phase 3 studies, and the company has not issued a release explaining the move.
  • BioRestorative Therapies, Inc. (NASDAQ:BRTX) rose about 8.0% near USD 1.62 intraday, after announcing a 1-for-20 reverse split on Wednesday, September 2, 2026 to regain compliance with the exchange's minimum bid price.
  • Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose about 8.63% to USD 1.07 from a prior close of about USD 0.985, while GRI Bio (NASDAQ:GRI) fell about 16.48% near USD 0.7851, both without a release.
  • The common theme is that none of the four has issued a release for Monday, and each is a clinical-stage company with no product revenue, a price near USD 1.00 and a dependence on equity funding.

Neumora (NASDAQ:NMRA): a rebound below USD 1.00 after a Phase 3 failure

Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage neuroscience company, rose about 7.9% in early trading on Monday, October 26, 2026, with prices described as intraday and near USD 0.41. On Monday, June 15, 2026 the company reported that navacaprant missed its primary endpoint in two Phase 3 studies, and the shares closed about 48.6% lower that day. In KOASTAL-2 the drug changed depression scores by 12.2 points against 12.0 for placebo, and in KOASTAL-3 by 10.1 against 10.8.

The company discontinued navacaprant and reduced its workforce by about 35%, guiding to annualised savings of about USD 10 million and a cash runway into the third quarter of 2027. Value now rests on NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia and NMRA-215 for obesity. A price near USD 0.41 sits below the USD 1.00 minimum bid requirement, which can lead to a deficiency notice and later a reverse split, and early moves in a sharply fallen stock often reflect trading, not news.

NMRA-511 is due to complete a multiple ascending dose cohort in healthy elderly volunteers in the fourth quarter of 2026, and NMRA-898 has Phase 1 data due in the second half of 2026. A runway into the third quarter of 2027 may require new capital before the pipeline produces value.

BioRestorative (NASDAQ:BRTX): a post-split share base

BioRestorative Therapies, Inc. (NASDAQ:BRTX) develops cell-based therapies, with BRTX-100 as its lead candidate for degenerative disc disease. The shares rose about 8.0% in early trading on Monday, October 26, 2026, near USD 1.62, and the company has not issued a release explaining the move. On Wednesday, September 2, 2026, it announced a 1-for-20 reverse stock split to regain compliance with the exchange's minimum bid price rule, and it also announced completion of BRTX-100 Phase 2 manufacturing. Neither release is dated to Monday.

A reverse split combines shares, here 20 into one, which raises the quoted price without changing a holder's proportional ownership. It often leaves fewer shares in the float, so ordinary buying can lift the price several percentage points. Manufacturing completion matters for timing but is not efficacy data. The risks are a slide back below USD 1.00 and dilution, since a clinical-stage company without product revenue usually funds itself through share sales or warrants.

Estrella Immunopharma (NASDAQ:ESLA): milestone swings around USD 1.00

Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose about 8.63% to USD 1.07 in early trading on Monday, October 26, 2026, after a prior close of about USD 0.985, and the company has not issued a release explaining the move. It develops EB103, a CAR-T cell therapy for B-cell non-Hodgkin lymphoma, in the STARLIGHT-1 Phase 1/2 trial. The shares rose 68.35% on Wednesday, October 14, 2026, when a fifth trial site was activated, and fell 19.66% on Thursday, October 15, 2026, when the first two-infusion patient was reported.

Market capitalisation is near USD 42.8 million and the float about 17.22 million shares, so site news and rebounds from below USD 1.00 can produce large moves. Phase 1 data reported on Monday, February 9, 2026 showed a 100% complete response rate at Month 1 in the high-dose cohort of nine patients. A close below USD 1.00 on Friday, October 23, 2026 raises the risk of a bid price notice if it persists, and a company of this size will probably need to raise capital.

GRI Bio (NASDAQ:GRI): a sub-dollar fall on thin news

GRI Bio (NASDAQ:GRI), a clinical-stage biotechnology company that completed a reverse merger with Vallon Pharmaceuticals in 2023, traded about 16.48% lower, near USD 0.7851 intraday, in early trading on Monday, October 26, 2026. The company has not issued a release explaining the move. Its most recent clinical news came on Monday, August 24, 2026, when it said it would present late-breaking Phase 2a data for GRI-0621, an experimental therapy for idiopathic pulmonary fibrosis, at the European Respiratory Society congress.

With no marketed product, valuation rests on trial results and access to cash. A notice can follow if the closing bid stays under USD 1.00 for 30 consecutive business days, and the company has previously regained compliance, according to a published item. The annual stockholder meeting proxy proposals commonly seek approval for reverse splits or higher share authorisations, either of which can weigh on the price.

The risks are financing, since a clinical-stage company with no revenue usually raises cash through equity offerings and warrants that dilute holders, and listing compliance, because a price near USD 0.79 may require a reverse split. GRI-0621 data from a small Phase 2a study may not be confirmed in larger trials, and intraday moves of this size on thin volume can reverse.

Where Things Stand

The answer is that sub-dollar and near-dollar biotechs trade on listing and funding mechanics when no news arrives. Neumora (NASDAQ:NMRA) has a runway into the third quarter of 2027 but a price near USD 0.41, and BioRestorative (NASDAQ:BRTX) has used a 1-for-20 split to stay above the bid threshold. Estrella Immunopharma (NASDAQ:ESLA) swung 68.35% and 19.66% in two sessions in mid-October before its 8.63% rise, and GRI Bio (NASDAQ:GRI) fell 16.48% below USD 1.00. The next catalysts are the Fed decision on Wednesday, October 28, 2026, the Neumora NMRA-898 Phase 1 data in the second half of 2026, the GRI Bio annual meeting results and any exchange notices. Intraday moves can reverse, and this is not investment advice.